Press Release

For Immediate Release

Granules India appoints Sucharita Rao Palepu as

Non-executive Independent Director

Hyderabad, 23rd Dec, 2021: Granules India Limited, a vertically integrated pharmaceutical company, today announced the appointment of Mrs Sucharita Rao Palepu as Non-executive Independent Director on the Board of the Company with immediate effect. Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services. She is currently a Strategic Advisor specializing in Organization & HR Transformation initiatives, prior to which, she was Global Head- Human Resources at Tech Mahindra Ltd.

Commenting on the appointment, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, "Further strengthening the Board of Directors, we welcome Sucharita as non- executive Independent Director. Her experience in Organization & HR Transformation initiatives and commercial orientation will be an added asset for us."

Over her career, Sucharita was instrumental in initiating several significant transformation programs and large- scale HR interventions, with a proven track record of delivering successful change in a global, diverse, multi- cultural and complex environment. With a strong commercial orientation, she is known for bringing about pioneering changes across various initiatives.

She was awarded Exemplary Woman in Leader Award (APAC) in HR Branding Awards 2015-16 and Women Super Achievers Award in HR Branding Awards 2009-10.

***END***

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best in class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain - from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6

CIN: L24110TG1991PLC012471 / Granules India Limited: 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad- 500081

are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Safe Harbor: This document is to provide the general background information about the Company's activities as at the date of the release. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Investor Contacts:

Krishna Raghunathan

Chaitanya Tummala

Vice President - Finance and Investor Relations

Company Secretary

040-69043573

040-69043614

krishna.raghunathan@granulesindia.com

chaitanya.tummala@granulesindia.com

CIN: L24110TG1991PLC012471 / Granules India Limited: 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad- 500081

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Granules India Limited published this content on 04 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2022 05:48:02 UTC.